Advances in the diagnosis and treatment of neuroblastoma

Joanna L. Weinstein, Howard M. Katzenstein, Susan L. Cohn*

*Corresponding author for this work

Research output: Contribution to journalReview article

181 Citations (Scopus)

Abstract

Neuroblastoma, a childhood neoplasm arising from neural crest cells, is characterized by a diversity of clinical behavior ranging from spontaneous remission to rapid tumor progression and death. To a large extent, outcome can be predicted by the stage of disease and the age at diagnosis. However, the molecular events responsible for the variability in response to treatment and the rate of tumor growth remain largely unknown. Over the past decade, transformation-linked genetic changes have been identified in neuroblastoma tumors that have contributed to the understanding of tumor predisposition, metastasis, treatment responsiveness, and prognosis. The Children's Oncology Group recently developed a Neuroblastoma Risk Stratification System that is currently in use for treatment stratification purposes, based on clinical and biologic factors that are strongly predictive of outcome. This review discusses the current risk-based treatment approaches for children with neuroblastoma and recent advances in biologic therapy.

Original languageEnglish (US)
Pages (from-to)278-292
Number of pages15
JournalOncologist
Volume8
Issue number3
DOIs
StatePublished - Jun 12 2003

Fingerprint

Neuroblastoma
Neoplasms
Spontaneous Remission
Genetic Transformation
Therapeutics
Biological Therapy
Neural Crest
Biological Factors
Neoplasm Metastasis
Growth

Keywords

  • Immunotherapy
  • Neuroblastoma
  • Retinoids
  • Risk-based therapy
  • Tumor biology

ASJC Scopus subject areas

  • Cancer Research
  • Hematology

Cite this

Weinstein, Joanna L. ; Katzenstein, Howard M. ; Cohn, Susan L. / Advances in the diagnosis and treatment of neuroblastoma. In: Oncologist. 2003 ; Vol. 8, No. 3. pp. 278-292.
@article{70a781fb3a294d718e2d5b1044602dfc,
title = "Advances in the diagnosis and treatment of neuroblastoma",
abstract = "Neuroblastoma, a childhood neoplasm arising from neural crest cells, is characterized by a diversity of clinical behavior ranging from spontaneous remission to rapid tumor progression and death. To a large extent, outcome can be predicted by the stage of disease and the age at diagnosis. However, the molecular events responsible for the variability in response to treatment and the rate of tumor growth remain largely unknown. Over the past decade, transformation-linked genetic changes have been identified in neuroblastoma tumors that have contributed to the understanding of tumor predisposition, metastasis, treatment responsiveness, and prognosis. The Children's Oncology Group recently developed a Neuroblastoma Risk Stratification System that is currently in use for treatment stratification purposes, based on clinical and biologic factors that are strongly predictive of outcome. This review discusses the current risk-based treatment approaches for children with neuroblastoma and recent advances in biologic therapy.",
keywords = "Immunotherapy, Neuroblastoma, Retinoids, Risk-based therapy, Tumor biology",
author = "Weinstein, {Joanna L.} and Katzenstein, {Howard M.} and Cohn, {Susan L.}",
year = "2003",
month = "6",
day = "12",
doi = "10.1634/theoncologist.8-3-278",
language = "English (US)",
volume = "8",
pages = "278--292",
journal = "Oncologist",
issn = "1083-7159",
publisher = "AlphaMed Press",
number = "3",

}

Advances in the diagnosis and treatment of neuroblastoma. / Weinstein, Joanna L.; Katzenstein, Howard M.; Cohn, Susan L.

In: Oncologist, Vol. 8, No. 3, 12.06.2003, p. 278-292.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Advances in the diagnosis and treatment of neuroblastoma

AU - Weinstein, Joanna L.

AU - Katzenstein, Howard M.

AU - Cohn, Susan L.

PY - 2003/6/12

Y1 - 2003/6/12

N2 - Neuroblastoma, a childhood neoplasm arising from neural crest cells, is characterized by a diversity of clinical behavior ranging from spontaneous remission to rapid tumor progression and death. To a large extent, outcome can be predicted by the stage of disease and the age at diagnosis. However, the molecular events responsible for the variability in response to treatment and the rate of tumor growth remain largely unknown. Over the past decade, transformation-linked genetic changes have been identified in neuroblastoma tumors that have contributed to the understanding of tumor predisposition, metastasis, treatment responsiveness, and prognosis. The Children's Oncology Group recently developed a Neuroblastoma Risk Stratification System that is currently in use for treatment stratification purposes, based on clinical and biologic factors that are strongly predictive of outcome. This review discusses the current risk-based treatment approaches for children with neuroblastoma and recent advances in biologic therapy.

AB - Neuroblastoma, a childhood neoplasm arising from neural crest cells, is characterized by a diversity of clinical behavior ranging from spontaneous remission to rapid tumor progression and death. To a large extent, outcome can be predicted by the stage of disease and the age at diagnosis. However, the molecular events responsible for the variability in response to treatment and the rate of tumor growth remain largely unknown. Over the past decade, transformation-linked genetic changes have been identified in neuroblastoma tumors that have contributed to the understanding of tumor predisposition, metastasis, treatment responsiveness, and prognosis. The Children's Oncology Group recently developed a Neuroblastoma Risk Stratification System that is currently in use for treatment stratification purposes, based on clinical and biologic factors that are strongly predictive of outcome. This review discusses the current risk-based treatment approaches for children with neuroblastoma and recent advances in biologic therapy.

KW - Immunotherapy

KW - Neuroblastoma

KW - Retinoids

KW - Risk-based therapy

KW - Tumor biology

UR - http://www.scopus.com/inward/record.url?scp=0038697907&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038697907&partnerID=8YFLogxK

U2 - 10.1634/theoncologist.8-3-278

DO - 10.1634/theoncologist.8-3-278

M3 - Review article

VL - 8

SP - 278

EP - 292

JO - Oncologist

JF - Oncologist

SN - 1083-7159

IS - 3

ER -